Effects Of Exogenous Human BMP-2, -3, -6, And -12 On Osteosarcoma Cell Lines

BACKGROUNDS AND OBJECTIVES:Osteosarcoma is the most common primary malignant tumor of bone. Its victims are usually young people. The current multimodal treatment of osteosarcoma consists of limb salvage surgry preceded and follwed by multidrug systemic chemotherapy. The 5- year disease free survival rate is 60-80%. However, approximately 40-50% of patients still develop distant metastasis and recurrence, and metastatic or recurrent tumors are significantly less sensitive, if not resistant, to conventional chemotherapy. At the same time, the other problem is how to promote the reconstruction and and rehabilitation of bone defects.Bone morphogenetic proteins (BMPs), members of the transforming growth factor-β(TGF-β) superfamily, have been implicated in bone formation and bone cell differentiation. At least 20 members of BMPs family have been reported. Clinical trials of recombinant human BMP2 and BMP7 were underway in patients with open tibial shaft fractures and in patients with a deficiency of the alveolar ridge. However, there are some differences in the osteoinductive activities of the family members. For...